"When I was younger and had no idea what was going on, I lived in a constant state of terror. The voices and delusions were ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, ...

The following is a summary of “Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study,” published in the ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Here’s what to know about the symptoms of schizoaffective disorder and schizophrenia, the differences between the two, and treatment options for each. Schizophrenia is a rare but serious mental ...